Pfizer's Flu Shot Just Beat the Flu Shot

On safety, the profile was largely comparable. Serious adverse events were similar between groups. The mRNA group did see more of the usual suspects (sore arms, fatigue, headaches), but those reactions were mild to moderate and faded quickly. If you've had a COVID mRNA shot, you know the drill.

The Race Pfizer Can't Afford to Lose

Pfizer isn't the only company trying to reinvent the flu shot with mRNA. In fact, they might not even be first to market.

Moderna has already filed for approval of its own mRNA flu vaccine, mRNA-1010, in the U.S., Europe, Canada, and Australia. Analysts expect an FDA decision by August 2026, potentially in time for the 2026-2027 flu season. When Moderna released its own Phase 3 data showing superiority over a standard-dose comparator, its stock jumped 16%. Evercore ISI, Goldman Sachs, and Piper Sandler all came out with bullish price targets.

Then there's GSK, which partnered with CureVac to develop its own mRNA flu candidate. They reported strong Phase 2 results.

Meanwhile, Sanofi (the company whose vaccine Pfizer just beat) made a surprising move: it scrapped its seasonal mRNA flu program entirely, deciding the technology wasn't mature enough to replace its blockbuster traditional portfolio. That's a bold bet on the old guard.

So the 2026-2027 landscape is shaping up like a three-horse race: Moderna slightly ahead, Pfizer right behind, and GSK/CureVac as a fast follower. The global flu vaccine market is worth roughly $9.7 billion in 2026 and growing, which means there's plenty of revenue to fight over.

The Elephant in the Room: Pfizer's Combo Problem

The standalone flu data looks solid. But Pfizer's bigger commercial dream is a combination vaccine that packages flu and COVID-19 protection into a single shot. That's where the real money lives; it's the difference between selling a hamburger and selling the whole meal.

Unfortunately, the combo program hit a speed bump. In Phase 3, the combined flu/COVID vaccine met its goals for influenza A and COVID-19, but failed non-inferiority for influenza B. Sound familiar? It's the same B-strain weakness showing up again. Pfizer has described the results as requiring further evaluation and is talking to regulators about next steps.

This matters because Wall Street has been relatively measured in its reaction to the standalone flu data. The reason: for a company Pfizer's size, a standalone mRNA flu shot is a nice addition to the portfolio, not a game-changer. The combo vaccine is the real growth engine, and it needs work.

Why This Still Matters

Step back from the stock price for a second and consider what just happened. An mRNA flu vaccine proved it can meaningfully outperform the standard of care in a large, well-designed trial. That's not incremental. That's a proof of concept for an entirely new generation of flu vaccines.

The standard flu shot is manufactured using eggs (yes, chicken eggs) in a process that takes months and often leads to mismatches between the vaccine strain and the actual circulating virus. mRNA vaccines can be updated faster and don't depend on egg-based manufacturing. If the A-strain superiority holds up across multiple seasons, the case for switching becomes very hard to ignore.

There's a regulatory wildcard, though. The FDA recently issued a "refuse to file" letter to Moderna's mRNA flu vaccine application, which analyst Mani Foroohar at Leerink interpreted as a sign of tighter scrutiny toward new mRNA vaccines under current agency leadership. If the regulatory bar is rising, both Pfizer and Moderna could face a longer path to market than their trial data alone would suggest.

For now, Pfizer has proven something important: its mRNA platform works for flu, not just COVID. The B-strain gap needs solving, the combo program needs fixing, and the regulatory environment is uncertain. But the foundation is there. The C+ era of flu vaccines might finally be ending. The question is whether Pfizer will be the one to end it, or if it'll be watching from the sidelines while Moderna crosses the finish line first.

The $11.75 Billion Bet That Rewrites Indian Pharma's Playbook

Sun Pharma just agreed to buy Organon for $11.75 billion, making it the largest overseas acquisition ever by an Indian pharma company. The deal is either a masterclass in disciplined dealmaking or a high-wire act with $8.6 billion in inherited debt.